NCT04300192View on ClinicalTrials.gov

Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa

PHASE4CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

January 11, 2023

Study Completion Date

January 11, 2023

Conditions
Pertussis ImmunisationDiphtheria ImmunisationTetanus ImmunisationPoliomyelitis Vaccine
Interventions
BIOLOGICAL

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine

Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Trial Locations (3)

1055

Investigational Site Number : 7100002, Middelburg

1619

Investigational Site Number : 7100003, Johannesburg

7925

Investigational Site Number : 7100001, Cape Town

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04300192 - Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa | Biotech Hunter | Biotech Hunter